Home
Resources
Publications
Indirubin 3'-oxime Inhibits Anticancer Agent-Induced YB-1 Nuclear Translocation in HepG2 Human Hepatocellular Carcinoma Cells

Indirubin 3'-oxime Inhibits Anticancer Agent-Induced YB-1 Nuclear Translocation in HepG2 Human Hepatocellular Carcinoma Cells

Toru Tanaka, Sachiyo Ohashi, Hiroaki Saito, Taira Wada, Tadashi Aoyama, Yoshimi Ichimaru, Shinichi Miyairi, Shunsuke Kobayashi

Biochem Biophys Res Commun. 2018 Jan 29;496(1):7-11.

PMID: 29274785

Abstract:

Hepatocellular carcinoma (HCC) is a disease with poor prognosis. Nuclear accumulation of YB-1 is closely related to the malignancy of HCC. Treatment with anticancer agents often induces translocation of YB-1 from cytoplasm to nucleus and activates the expression of multidrug resistance gene 1 (MDR1). Therefore, any effective inhibitor of this phenomenon would be useful for cancer treatment. Here we examined various indirubin derivatives and found that indirubin 3'-oxime inhibits actinomycin D-induced nuclear transport of YB-1 and suppresses the activation of MDR1 gene expression in the human hepatocellular carcinoma cell line HepG2. Furthermore, use of both indirubin 3'-oxime and actinomycin D in combination increased the anticancer effect on HepG2 cells. Indirubin 3'-oxime is a novel and efficient inhibitor of anticancer agent-induced YB-1 nuclear translocation.

Chemicals Related in the Paper:

Catalog Number	Product Name	Structure	CAS Number	Price
AP160807498-A	Indirubin-3′-oxime		160807-49-8	Price

As a specialist in analytical chemical Products, Alfa Chemistry offers consumers a wealth of raw materials and a full range of technologies and services.

QUICK LINKS

HEADQUARTERS

Tel:

Fax:

Email: